Researchers identify possible candidates for multipotent stem cells in the sea anemone

PHILADELPHIA — How do other countries achieve better health outcomes than the U.S.? They all have three traits that the U.S. does not, Paul Keckley,

Mobocertinib (Exkivity) will be withdrawn from the U.S. market after a failed confirmatory trial in non-small cell lung cancer (NSCLC) patients with EGFR exon 20

Two Bay Area ven­ture cap­i­tal firms that in­vest in biotech star­tups — but al­so put their mon­ey be­hind a broad­er swath of nascent com­pa­nies in